文献速递妇科

病理化疗反应评分在输卵管-卵巢高级别浆液性癌中的预后价值:基于个体患者数据的系统综述与Meta分析

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
PubMed 文献 · Gynecol Oncol · 2019-05-19

该系统综述与Meta分析汇总11个国家16个中心的877例接受新辅助化疗的输卵管-卵巢高级别浆液性癌患者个体数据,评估化疗反应评分(CRS)的预后价值。CRS3与CRS1/CRS2相比,无进展生存期和总生存期的合并风险比分别为0.55(95%CI 0.45-0.66,P<0.001)和0.65(95%CI 0.50-0.85,P=0.002),均显著改善且无异质性。作者认为CRS是稳健可重复的生物标志物,可能纳入治疗决策和临床试验设计。

要点

  • CRS3患者占28%(249/877),其无进展生存期和总生存期均显著优于CRS1/CRS2患者。
  • CRS3 vs CRS1/CRS2的合并HR:无进展生存期0.55(95%CI 0.45-0.66,P<0.001),总生存期0.65(95%CI 0.50-0.85,P=0.002)。
  • 在已知胚系BRCA1/2状态的306例患者中,BRCA1/2突变者(n=80)更易达到CRS3(P=0.027)。

核心结论

  • CRS3与CRS1/CRS2相比,无进展生存期和总生存期均显著改善。
  • CRS在真实世界中的验证表明其为稳健可重复的生物标志物,可能纳入治疗决策和临床试验设计。

研究设计与样本

  • 国际协作开展的系统综述与Meta分析,汇总11个国家16个中心的个体患者数据。
  • 纳入患者为IIIC/IV期输卵管-卵巢高级别浆液性癌,接受3-4个周期新辅助化疗,随访>6个月。
  • 共纳入877例患者,来自已发表和未发表研究。
  • 采用随机效应模型计算合并比值比,分析CRS与无进展生存期和总生存期的关联。

主要发现

  • 中位无进展生存期15个月(IQR 5-65),中位总生存期28个月(IQR 7-92)。
  • CRS3见于249例患者(28%)。
  • CRS3 vs CRS1/CRS2的无进展生存期合并HR为0.55(95%CI 0.45-0.66,P<0.001),总生存期合并HR为0.65(95%CI 0.50-0.85,P=0.002)。
  • 未发现异质性(无进展生存期:Q=6.42,P=0.698,I²=0.0%;总生存期:Q=6.89,P=0.648,I²=0.0%)。
  • 在调整年龄和分期的多变量模型中,CRS与无进展生存期和总生存期仍显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT. METHODS: We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3-4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS). RESULTS: 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5-65) and 28 months (IQR 7-92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45-0·66; P < 0·001) and 0·65 (95% CI 0·50-0·85, P = 0·002) respectively; no heterogeneity was identified (PFS: Q = 6·42, P = 0·698, I2 = 0·0%; OS: Q = 6·89, P = 0·648, I2 = 0·0%). CRS was significantly associated with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0·027). CONCLUSIONS: CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This validation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with potential to be incorporated into therapeutic decision-making and clinical trial design.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cohen PA, Powell A, Böhm S, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019. PMID: 31118141. doi:10.1016/j.ygyno.2019.04.679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。